Allen & Overy’s Nicole Daley on the rebound in M&A activity in the pharma industry
Related people
Headlines in this article
Related news and insights
Publications: 05 April 2024
National Security Division Announces New Self-Disclosure Policy in M&A Transactions
News: 01 April 2024
News: 15 March 2024
Allen & Overy advises Zendesk on its acquisition of AI-powered service automation leader Ultimate
Publications: 11 March 2024
Nicole Daley, life sciences and M&A partner at Allen & Overy, discussed the steady pickup in M&A in the pharma industry after years of underperformance with PharmaVoice.
Nicole shared her thoughts on portfolio diversification and additive dealmaking, and how companies with a sharper focus can be more appealing to investors in the life sciences arena.
Read the full PharmaVoice article here.
Disclaimer:
First published on PharmaVoice.com on the 19th March.